Skip to main content
. 2018 Oct 26;19(11):3352. doi: 10.3390/ijms19113352

Figure 13.

Figure 13

Cell representation (%) within the four quadrants for HME50-5E cell treatment. Percent distribution of HME50-5E apoptotic cells after treatment with H2O2, Sutent, Selenite as Se, Bevacizumab (BV), Selenobevacizumab (Se-BV), Trastuzumab (TZ) or Selenotrastuzumab (Se-TZ). Data is expressed as Mean (n = 3).